Tissue Perfusion Pressure to Guide Circulatory Shock Care
Official title: Tissue Perfusion Pressure for Improved Management of Circulatory Shock
Funded at Massachusetts General Hospital · NIH-11326271 · Data updated 2026-11-12
A new measure called tissue perfusion pressure (TPP) will be studied to guide treatment of circulatory shock in ICU patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | July 1, 2024 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $768,543 |
| NIH project number | 5R01HL173544-03 |
| Project ID | NIH-11326271 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with circulatory shock in intensive care units who require blood pressure management.
✕Less likely to help
Patients without circulatory shock or those not needing blood pressure optimization may not benefit.
What this research studies
In this project at Massachusetts General Hospital, researchers will analyze patient data to define tissue perfusion pressure, which is the difference between mean arterial pressure and the pressure at which blood flow stops. They aim to use this metric to tailor therapies for people with shock due to heart failure, sepsis, or hemorrhage. The study builds on prior findings from thousands of patients and seeks to move beyond MAP as the sole target. The goal is to improve how we personalize treatment and potentially prevent organ injury and death.
Why it matters
Potential benefit: If successful, patients with circulatory shock could receive more personalized and effective blood pressure targets, potentially improving survival and organ function.
How similar studies have gone: Earlier trials showed mixed results for higher vs lower MAP; this work proposes a new metric (TPP) that may better predict tissue perfusion.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Aguirre, Aaron D — Massachusetts General Hospital
- Study coordinator: Aguirre, Aaron D
Related research
Other NIH-funded projects on the same topics.
-
Pragmatic midodrine trial to reduce ICU vasopressor use in septic shock
A practical, patient-focused trial tests whether taking oral midodrine can lessen the need for IV vasopressors and shorten ICU stays for people with sepsis-related low blood pressure.
-
Understanding how small heat shock proteins protect our cells
A study from the University of Washington explores how tiny chaperone proteins protect eye and other cells from damage, which could help prevent conditions like cataracts and age-related macular degeneration.
-
A new approach to freeing HIV from brain cells and reducing brain inflammation
A patient-focused approach tests a strategy to flush out hidden HIV in the brain and protect brain health by reducing inflammation.
-
Shock patients: better, faster teamwork to find the cause
A team of clinicians works together to quickly identify the exact cause of a patient’s shock to guide the right treatment.
-
Multi-scale model to improve REBOA use in hemorrhagic shock
A researcher team is building a computer model to better predict how to use REBOA, a device that can control bleeding in the torso, so patients with severe trauma may survive.
-
Phospholipid nanoparticle fluid to replace blood volume and protect organs in severe bleeding
A new, bubble-free fluid made of tiny lipid particles is being developed to quickly restore blood volume and protect organs during severe bleeding when real blood isn’t available.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.